AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 34927293
Drug: C (control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C (control group, 0 g ML powder per sow per day)
Trial: 34668795
Drug: Multimodal nonopioid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multimodal nonopioid analgesic protocol (acetaminophen, ketorolac, diazepam, gabapentin, and meloxicam)
Trial: 34668795
Drug: Standard opioid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard opioid regimen (hydrocodone‐acetaminophen)
Trial: 34391876
Drug: Multimodal nonopioid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multimodal nonopioid analgesic protocol
Trial: 35331859
Drug: NSAID (loxoprofen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NSAID (loxoprofen sodium, 180 mg/day for 5 weeks)
Trial: 33407791
Drug: Intra-articular injections
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular injections of 5 ml isotonic saline every second week for a total of 4 injections
Trial: 34473194
Drug: Ensartinib, 225
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ensartinib, 225 mg once daily
Trial: 34473194
Drug: Crizotinib, 250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crizotinib, 250 mg twice daily
Trial: 33180670
Drug: AS04-adjuvanted HPV-16/18
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AS04-adjuvanted HPV-16/18 vaccine
Trial: 34764183
Drug: 6-week twice-weekly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6-week twice-weekly regimen of rifapentine plus isoniazid
Trial: 34672928
Drug: 1-day acceptance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-day acceptance and commitment therapy (ACT) workshop
Trial: 36916653
Drug: Topical tacrolimus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical tacrolimus (TAC)
Trial: 33542412
Drug: Hylan G-F
RxNorm normalized name: hylan G-F 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hylan G-F 20 (HG)
Trial: 32482355
Drug: 0.2 μg.kg−1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 μg.kg−1 remifentanil combined with propofol
Trial: 32482355
Drug: 0.3 μg.kg−1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 μg.kg−1 remifentanil combined with propofol
Trial: 32610864
Drug: Daily oral
RxNorm normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily oral iron supplementation (60mg of elemental iron, ferrous sulfate)
Trial: 32610864
Drug: Alternate day
RxNorm normalized name: Alternaria alternata
DrugBank: Alternaria alternata (DB10424)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alternate day oral iron supplementation (60mg of elemental iron, ferrous sulfate)
Trial: 32610864
Drug: Alternate day
RxNorm normalized name: Alternaria alternata
DrugBank: Alternaria alternata (DB10424)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alternate day oral iron supplementation
Trial: 34105575
Drug: 3 whole
RxNorm normalized name: Rubivirus rubella virus Wistar RA 27/3 whole
DrugBank: Rubella virus vaccine (DB10317)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 whole Gala apples (∼200 g)
Trial: 35142833
Drug: Computer-Assisted Cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Computer-Assisted Cognitive Behavior Therapy (CCBT)
Trial: 33361317
Drug: Navy bean
RxNorm normalized name: navy bean
DrugBank: Kidney bean (DB10639)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Navy bean intervention (35 g bean powder/day)
Trial: 34383381
Drug: MMC + cytosine arabinoside
RxNorm normalized name: Cytosine arabinoside
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: MMC + cytosine arabinoside (Ara‐C) therapy (30 mg/30 mL + 200 mg/10 mL) for 6 weeks
Trial: 34383381
Drug: Mitomycin C
RxNorm normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mitomycin C (MMC) therapy (30 mg/40 mL) for 6 weeks
Trial: 34383381
Drug: MMC + Ara‐C therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MMC + Ara‐C therapy
Trial: 34383381
Drug: MMC therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MMC therapy
Trial: 34383381
Drug: MMC and
RxNorm normalized name: MMC
DrugBank: Mitomycin (DB00305)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: MMC and Ara‐C therapy
Trial: 32114796
Drug: Twice-daily 30-second
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice-daily 30-second ECGs during 14 days
Trial: 32641226
Drug: Valsartan 160
RxNorm normalized name: valsartan 160 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valsartan 160 mg twice daily
Trial: 33113452
Drug: Brief Cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brief Cognitive Behavioral Therapy for Suicide Prevention (BCBT)
Trial: 32588803
Drug: Vi-polysaccharide (ViPS)
RxNorm normalized name: Typhoid Vi polysaccharide vaccine
DrugBank: Typhoid Vi polysaccharide vaccine (DB10803)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vi-polysaccharide (ViPS) typhoid vaccine
Trial: 32314015
Drug: 3 mg
RxNorm normalized name: boron 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg vaginal dinoprostone
Trial: 35771891
Drug: Intravenous iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous iron isomaltoside (20 mg.kg‐1 up to 1000 mg over 30 minutes)
Trial: 34593344
Drug: Intervention involving
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intervention involving the use of the PADR-EC ADR score communicated to clinicians and discussed with participants, followed by medication management advice to general practitioners and community pharmacists.
Trial: 33491087
Drug: Intensive therapy
RxNorm normalized name: Cortaid Intensive Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive therapy (HbA1c < 6.2%, blood pressure < 120/75 mm Hg, LDL-cholesterol < 80 mg/dL)
Trial: 33491087
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy (HbA1c < 6.9%, blood pressure < 130/80 mm Hg, LDL-cholesterol < 120 mg/dL)
Trial: 33491087
Drug: Administration of
RxNorm normalized name: IV solutions used in parenteral administration of fluids, electrolytes and nutrients
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of pioglitazone at 1 year after randomization
Trial: 32004772
Drug: Fluvastatin (multiple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvastatin (multiple oral doses: 20, 40 or 80 mg/day for 7 days)
Trial: 32004772
Drug: Atorvastatin (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin (single oral dose: 20, 40 or 80 mg)
Trial: 34032727
Drug: Diltiazem (90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem (90 mg qd diltiazem sustained-release capsules)
Trial: 34032727
Drug: Nicorandil (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicorandil (5 mg tid nicorandil tablets)
Trial: 34032727
Drug: Routine drug
RxNorm normalized name: Peace Out Acne Hero Routine KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine drug treatments (aspirin, atorvastatin, betaloc ZOK, perindopril, and isosorbidemononitrate sustained-release tablets)
Trial: 32854772
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg OD Rivaroxaban treatment for 11 to 17 days
Trial: 35622608
Drug: Injection of
RxNorm normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of the pretarsal segment of the upper eyelid
Trial: 38356864
Drug: Antibiotic use
RxNorm normalized name: Antibiotics for systemic use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic use
Trial: 32556710
Drug: Biofeedback therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biofeedback therapy in addition to standard urotherapy
Trial: 33233717
Drug: Usual treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual treatment for postpartum depression provided in healthcare centers
Trial: 33233717
Drug: Usual treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual treatment for postpartum depression
Trial: 32303437
Drug: Anti-EGFR agents
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-EGFR agents exposure
Trial: 33097365
Drug: Voice treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Voice treatment with physiologic voice therapy plus vocal hygiene program (n = 17)
Trial: 33988941
Drug: Manual therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual therapy and sacroiliac joints home‐based exercise program
Trial: 33988941
Drug: Sacroiliac joints
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sacroiliac joints manual therapy and home‐based lumbar exercise program
Trial: 32278735
Drug: Chronic kidney
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chronic kidney disease defined by an eGFR < 60 mL/min/1.73 m2
Trial: 32278735
Drug: Nephrotoxic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nephrotoxic treatment
Trial: 33551165
Drug: 0 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 g/d of YS powder
Trial: 33551165
Drug: 3 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g/d of YS powder
Trial: 33551165
Drug: 6 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 g/d of YS powder
Trial: 33551165
Drug: 9 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 9 g/d of YS powder
Trial: 35306405
Drug: daridorexant 50
RxNorm normalized name: daridorexant 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: daridorexant 50 mg
Trial: 32696600
Drug: Daily step
RxNorm normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Daily step count during quarantine
Trial: 32696600
Drug: Average daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Average daily step count before and during quarantine
Trial: 35638548
Drug: Upfront ABVD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Upfront ABVD plus radiation therapy
Trial: 35638548
Drug: Baseline TMTV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline TMTV ≥155 mL
Trial: 33097977
Drug: Ibuprofen 400
RxNorm normalized name: ibuprofen 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen 400 mg orally 1 hour before ESP
Trial: 33097977
Drug: Low-level laser
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-level laser therapy (single session immediately after ESP)
Trial: 33097977
Drug: Placebo lactose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo lactose tablets orally 1 hour before ESP
Trial: 36285484
Drug: Prism adaptation
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prism adaptation training during standard occupational therapy sessions for three weeks.
Trial: 36285484
Drug: Standard occupational
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard occupational therapy (control group).
Trial: 33124670
Drug: Insulin independence
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin independence
Trial: 32290122
Drug: GS mint
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GS mint (4 mg of gymnemic acids)
Trial: 32891709
Drug: n-acetylcysteine 1.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n-acetylcysteine 1.2 g
Trial: 32891709
Drug: n-acetylcysteine 2.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n-acetylcysteine 2.4 g
Trial: 32588088
Drug: Complex model
RxNorm normalized name: hesperidin complex
DrugBank: Citrus bioflavonoids (DB14586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Complex model (combination of radiomic and clinical models)
Trial: 32776099
Drug: Nomogram including
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Nomogram including age, race, tumor site, depth of tumor invasion, lymph node status, distant metastasis, tumor size, surgery, chemotherapy and radiotherapy.
Trial: 32789505
Drug: Low-dose (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose (2.5 μg/dose)
Trial: 32789505
Drug: Medium-dose (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium-dose (5 μg/dose)
Trial: 32789505
Drug: High-dose (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose (10 μg/dose)
Trial: 32789505
Drug: Vaccine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccine (5 μg/dose) on days 0 and 14
Trial: 32789505
Drug: Vaccine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccine (5 μg/dose) on days 0 and 21
Trial: 32156534
Drug: Organic Zinc
RxNorm normalized name: ZINC OXIDE 25 g in 100 g TOPICAL LOTION [ORGANIC ZINCLEAR SUNSCREEN]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Organic Zinc (Zn) 20 mg/kg DM
Trial: 32156534
Drug: Organic Zinc
RxNorm normalized name: ZINC OXIDE 25 g in 100 g TOPICAL LOTION [ORGANIC ZINCLEAR SUNSCREEN]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Organic Zinc (Zn) 40 mg/kg DM
Trial: 32156534
Drug: Organic Copper
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Organic Copper (Cu) 12.5 mg/kg DM
Trial: 32156534
Drug: Organic Zinc
RxNorm normalized name: ZINC OXIDE 25 g in 100 g TOPICAL LOTION [ORGANIC ZINCLEAR SUNSCREEN]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Organic Zinc (Zn) 60 mg/kg DM
Trial: 32156534
Drug: Organic Copper
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Organic Copper (Cu) 25 mg/kg DM
Trial: 32156534
Drug: Organic Copper
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Organic Copper (Cu) 37.5 mg/kg DM
Trial: 32156534
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Zn 60 + Cu 37.5 mg/kg DM
Trial: 35084071
Drug: D-cycloserine (DCS)
RxNorm normalized name: D-Cycloserine
DrugBank: Cycloserine (DB00260)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: D-cycloserine (DCS) 35 or 70 mg + exposure therapy
Trial: 35084071
Drug: Placebo +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo + exposure therapy
Trial: 35084071
Drug: D-cycloserine (DCS)
RxNorm normalized name: D-Cycloserine
DrugBank: Cycloserine (DB00260)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: D-cycloserine (DCS) + exposure therapy
Trial: 32011017
Drug: Environmental exposures
RxNorm normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Environmental exposures (including socio-economic status, water source, sanitary facility, domestic animals, maternal characteristics, season, antibiotic use, and delivery mode)
Trial: 35787135
Drug: GCSF (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GCSF (300 μg subcutaneously administered two days after IUI)
Trial: 35846327
Drug: Progesterone +
RxNorm normalized name: Progesterone
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Progesterone + Metformin
Trial: 32060156
Drug: Standard SWMS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard SWMS care plus a targeted prescribing pathway for LIRA 3 mg
Trial: 33412557
Drug: Nifurtimox 10–20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifurtimox 10–20 mg/kg/day (aged <12 years) or 8–10 mg/kg/day (aged ≥12 years) for 60 days
Trial: 35301982
Drug: Ureteroscopic stone
RxNorm normalized name: ditch stonecroft extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ureteroscopic stone treatment
Trial: 35930976
Drug: High-flow normobaric
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-flow normobaric oxygen (NBO) by Venturi mask (FiO2 50%, flow 15 L/min) for 6 hours
Trial: 35930976
Drug: Routine low-flow
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine low-flow oxygen supplementation by nasal cannula (flow 3 L/min) for 6 hours
Trial: 32677170
Drug: Doublebase gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doublebase gel (DBG)
Trial: 32677170
Drug: Myribase gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Myribase gel (MBG)
Trial: 35219776
Drug: Olaparib (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olaparib (300 mg twice a day) with RDI >98%
Trial: 35219776
Drug: Olaparib (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olaparib (300 mg twice a day) with RDI 90%-98%
Trial: 35219776
Drug: Olaparib (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olaparib (300 mg twice a day) with RDI <90%
Trial: 32642957
Drug: Intranasal (IN)
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal (IN) ketamine (30 and 50 mg)
Trial: 33246021
Drug: Alpelisib (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpelisib (300 mg/day) plus fulvestrant (500 mg every 28 days and once on day 15)
Trial: 35750737
Drug: Amoxicillin 2
RxNorm normalized name: amoxicillin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin 2 grams preoperatively
Trial: 33002553
Drug: Vildagliptin 50
RxNorm normalized name: vildagliptin 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vildagliptin 50 mg/day with Metformin 1000 mg/day
Trial: 36309760
Drug: Enteral Nutrition
RxNorm normalized name: ENTERAL NUTRITION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enteral Nutrition (EN) starting on postoperative day (POD) 1 at 200-300 ml/day, increased to 400-600 ml/day on POD 2, depending on surgeon's decision from POD 3.
Trial: 36309760
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups start oral feeding on POD 3.
Trial: 34328151
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg of Salmon milt peptide (SMP) administered continuously or as a single dose for one week
Trial: 36164011
Drug: Rusfertide (10-120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rusfertide (10-120 mg weekly)
Trial: 36164011
Drug: Rusfertide (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rusfertide (40 mg SQ twice weekly)
Trial: 33119898
Drug: Venetoclax plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venetoclax plus azacitidine (AZA; 75 mg/m2; days 1-7)
Trial: 33119898
Drug: Venetoclax plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venetoclax plus decitabine (DEC; 20 mg/m2; days 1-5)
Trial: 34389504
Drug: Oral immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral immunotherapy for peanut allergy
Trial: 32578472
Drug: 7-day intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7-day intake of NZBC extract (600 mg containing 210 mg of anthocyanins)
Trial: 32578472
Drug: 14-day intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 14-day intake of NZBC extract (600 mg containing 210 mg of anthocyanins)
Trial: 33112049
Drug: Hazelnut oil
RxNorm normalized name: Hazelnut oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hazelnut oil containing 24.2 mg kg‐1 2‐MCPD and 54.5 mg kg‐1 3‐MCPD
Trial: 33112049
Drug: Background excretion
RxNorm normalized name: gonorrheal urethral secretion human
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Background excretion before exposure
Trial: 33546610
Drug: Oral nutritional
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral nutritional supplementation (ONS) combined with sit-to-stand (STS) exercises for 12 weeks
Trial: 616791867
Drug: TAS‐102 35
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAS‐102 35 mg/m² orally twice daily after meals on days 1 through 5 and 8 through 12 of each 28‐day cycle (n = 534)
Trial: 616791867
Drug: TAS‐102 35
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAS‐102 35 mg/m²
Trial: 33925049
Drug: 50% whole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50% whole grain cereals with 12 g sugar (50-WG)
Trial: 33925049
Drug: 0% whole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0% whole grain cereals with 24 g sugar (0-WG)
Trial: 33788461
Drug: Heat-sensitive moxibustion
RxNorm normalized name: Fluorimax Sensitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heat-sensitive moxibustion combined with western medication
Trial: 33788461
Drug: Simple western
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simple western medication (alendronate sodium tablet, calcium carbonate, vitamin D3 tablet)
Trial: 34252203
Drug: 8 L
RxNorm normalized name: PEG-8 laurate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 L of balanced hypotonic electrolyte supplement
Trial: 34252203
Drug: 1 to
RxNorm normalized name: Cep-11981 tosylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 to 3 L of water
Trial: 34252203
Drug: 8 L
RxNorm normalized name: PEG-8 laurate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 L of balanced hypotonic electrolyte supplement with 42K
Trial: 35213517
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg E2/100 mg P4
Trial: 35213517
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg E2/100 mg P4
Trial: 33420480
Drug: OCPs (0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OCPs (0.15 mg levonorgestrel + 0.30 μg ethinyl estradiol)
Trial: 33225772
Drug: Phototherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phototherapy plus UDCA (10 mg/kg/day)
Trial: 32875451
Drug: Pomegranate peel
RxNorm normalized name: Pomegranate
DrugBank: Pomegranate (DB14317)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pomegranate peel supplementation via water (0.3 g L‐1)